Paper

Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.

Published Aug 1, 2021 · Ding-wei Cang, Guoyou Zou, Chi Yang

Journal of pharmacological sciences

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCTAnimal Study

Study Snapshot

Dencichine alleviates ovariectomy-induced bone loss in mice and inhibits osteoclastogenesis in vitro, suggesting it could be a promising candidate for treating bone loss diseases like PMOP and rheumatoid arthritis.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Dencichine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis by inhibiting RANKL-associated NF-κB and MAPK signaling pathways.

References

Citations